8-K: bioAffinity Reports Record CyPath Lung Sales in Q3 2025

bioAffinity Technologies announced record sales for its CyPath Lung diagnostic test in the third quarter of 2025, driven by increased adoption in Veterans hospitals and mid-Atlantic market expansion.

Summary

• Sales of the CyPath Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025.
• Third quarter 2025 sales represent a 95% increase over the previous quarter.
• Sales for the first nine months of 2025 rose 97% compared to the same period in 2024.
• The growth is attributed to increasing adoption by Veterans hospitals and market expansion in the mid-Atlantic region.
• Performance metrics in the third quarter showed a 77% increase in the number of new patients using CyPath Lung.
• There was also greater patient compliance for at-home sample collection and return.

Sentiment

Score: 8

Explanation: The filing reports significant, record-breaking sales growth for its key diagnostic product, CyPath Lung, along with increased patient adoption and compliance. This indicates strong market traction and positive clinical impact, suggesting a very positive operational performance.

Positives

• Achieved record sales volume for the CyPath Lung diagnostic test in Q3 2025.
• Reported a significant 95% increase in sales over the previous quarter.
• Demonstrated strong year-over-year growth with a 97% increase in sales for the first nine months of 2025 compared to 2024.
• Experienced a 77% increase in new patients utilizing CyPath Lung during Q3 2025.
• Noted improved patient compliance for at-home sample collection and return.
• Gaining traction in the marketplace with increasing integration into clinical practice, reflecting growing physician confidence.
• CyPath Lung has shown clinical impact by detecting early-stage lung cancer and sparing patients from unnecessary invasive procedures.

Risks

• Various risks and uncertainties, many of which are difficult to predict, could cause actual results to differ materially from current expectations.
• The Company's ability to continue sales growth in 2025 and beyond is a factor that could impact actual results.

Future Outlook

The Company anticipates continued sales growth for CyPath Lung in 2025 and beyond, driven by increasing market adoption and integration into clinical practice, although this is subject to various risks and uncertainties.

Management Comments

• "The continued acceleration in CyPath Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, most treatable stages." Maria Zannes, President and CEO.
• "Physicians are equally impressed by CyPath Lung's ability to save patients from unnecessary invasive procedures when the nodule is benign." Maria Zannes, President and CEO.
• "Our strong quarter-over-quarter growth demonstrates that CyPath Lung is gaining traction in the marketplace, and we are encouraged by the test's increasing integration into clinical practice." Maria Zannes, President and CEO.
• "Every early cancer detected means a life that may be saved, and every unnecessary invasive procedure avoided means a patient spared from risk, anxiety and cost. This is why more physicians are adding CyPath Lung as an essential tool in the diagnostic pathway." Gordon Downie, MD, PhD, Chief Medical Officer.

Industry Context

The strong growth in CyPath Lung sales reflects a broader industry trend towards non-invasive diagnostic solutions, particularly in oncology, where early detection significantly improves patient outcomes. The adoption by Veterans hospitals highlights the potential for innovative diagnostics to penetrate large healthcare systems, while the mid-Atlantic expansion indicates successful regional market penetration strategies in a competitive diagnostic landscape.

Stakeholder Impact

• Shareholders: Positive impact due to strong sales growth and market adoption, potentially leading to increased company value.
• Patients: Positive impact through earlier detection of lung cancer, potentially saving lives and sparing patients from unnecessary invasive procedures.
• Physicians: CyPath Lung is gaining confidence as an essential diagnostic tool, aiding in clinical decision-making.
• Employees: Continued growth may lead to job security and potential expansion opportunities.

Next Steps

• Continue sales growth in 2025 and beyond.
• Expand marketing and sales efforts.
• Further integrate CyPath Lung into clinical practice.

Key Dates

Recommendation

The filing indicates robust operational performance with record sales and substantial growth rates for CyPath Lung, a key diagnostic product. The increasing adoption by healthcare providers, particularly Veterans hospitals, and market expansion suggest strong underlying demand and physician confidence. While general risks are acknowledged, the specific metrics presented are highly positive and point to strong momentum, making the stock an attractive investment for growth-oriented investors.

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer, diagnostic test, biotechnology, noninvasive diagnostics, Q3 2025 results, medical devices, AI diagnostics, Veterans hospitals